Fiche publication
Date publication
octobre 2006
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CHAIGNEAU Loïc
,
Dr FAGNONI Philippe
,
Pr PIVOT Xavier
,
Pr WORONOFF Macha
Tous les auteurs :
Fagnoni P, Limat S, Chaigneau L, Guardiola E, Briaud S, Schmitt B, Merrouche Y, Pivot X, Woronoff-Lemsi MC
Lien Pubmed
Résumé
INTRODUCTION: Anaemia is a common toxicity in cancer patients and epoetins (EPOs) are now an established treatment. The economic profile of EPO treatment was assessed in patients with breast cancer treated by adjuvant-chemotherapy. MATERIALS AND METHODS: Two strategies were compared: without treatment by EPO and with the possible use of treatment by EPO (epoetin alfa) when required. The clinical effectiveness criterion was time adjusted to quality of life and economic data included only direct medical costs. MAIN RESULTS: One hundred ninety-two patients were included. In the group with the strategy containing the possible use of EPO, 45.5% of patients effectively received EPO. A significant difference in the haemoglobin level profile over time was observed which provided a significant overall benefit of 0.0052 (p
Référence
Support Care Cancer. 2006 Oct;14(10):1030-7
